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Abstract
Background: Drug-induced liver injury (DILI) is a common complication of tuberculosis treatment. We utilised data
from the REMoxTB clinical trial to describe the incidence of predisposing factors and the natural history in patients
with liver enzyme levels elevated in response to tuberculosis treatment.
Methods: Patients received either standard tuberculosis treatment (2EHRZ/4HR), or a 4-month regimen in which
moxifloxacin replaced either ethambutol (isoniazid arm, 2MHRZ/2MHR) or isoniazid (ethambutol arm, 2EMRZ/2MR).
Hepatic enzymes were measured at 0, 2, 4, 8, 12 and 17 weeks and as clinically indicated during reported adverse
events. Patients included were those receiving at least one dose of drug and with two or more hepatic enzyme
measurements.
Results: A total of 1928 patients were included (639 2EHRZ/4HR, 654 2MHRZ/2MHR and 635 2EMRZ/2MR). DILI was
defined as peak alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal (5 × ULN) or ALT ≥ 3 × ULN with
total bilirubin > 2 × ULN. DILI was identified in 58 of the 1928 (3.0%) patients at a median time of 28 days (interquartile
range IQR 14–56). Of 639 (6.4%) patients taking standard tuberculosis therapy, 41 experienced clinically significant enzyme
elevations (peak ALT ≥ 3 × ULN). On standard therapy, 21.1% of patients aged >55 years developed a peak ALT/aspartate
aminotransferase (AST) ≥ 3 × ULN (p = 0.01) and 15% of HIV-positive patients experienced a peak ALT/AST ≥ 3 × ULN
compared to 9% of HIV-negative patients (p = 0.160). The median peak ALT/AST was higher in isoniazid-containing
regimens vs no-isoniazid regimens (p < 0.05), and lower in moxifloxacin-containing arms vs no-moxifloxacin arms
(p < 0.05). Patients receiving isoniazid reached a peak ALT ≥ 3 × ULN 9.5 days earlier than those on the ethambutol arm
(median time of 28 days vs 18.5 days). Of the 67 Asian patients with a peak ALT/AST ≥ 3 × ULN, 57 (85.1%) were on an
isoniazid-containing regimen (p = 0.008).
Conclusions: Our results provide evidence of the risk of DILI in tuberculosis patients on standard treatment. Older
patients on standard therapy, HIV-positive patients, Asian patients and those receiving isoniazid were at higher risk
of elevated enzyme levels. Monitoring hepatic enzymes during the first 2 months of standard therapy detected
approximately 75% of patients with a peak enzyme elevation ≥3 × ULN, suggesting this should be a standard of care.
These results provide evidence for the potential of moxifloxacin in hepatic sparing.
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Background
The combination of isoniazid, rifampicin, pyrazinamide
and ethambutol taken over at least 6 months has been
standard therapy for drug-sensitive tuberculosis (TB) for
over 30 years [1]. Liver enzyme elevations and drug-
induced liver injury (DILI) are recognised complications
for this regimen. They cause patient morbidity, treatment
interruption and poor treatment outcomes [2–4]. The re-
ported rates of significant liver enzyme elevation on stand-
ard therapy vary between 5% and 30% [5–8]. An increased
risk is associated with pre-existing liver disease, HIV infec-
tion, alcohol use, being female and increasing age [9–12].
Management guidelines for TB DILI are largely based
on expert opinion [6, 13, 14]. The British Thoracic Society
(BTS) guidelines recommend treatment interruption when
alanine aminotransferase (ALT) or aspartate aminotrans-
ferase (AST) are elevated to 5 times the upper limit of
normal (5 × ULN) or when bilirubin rises above the ULN
[13]. The American Thoracic Society (ATS), in contrast,
recommends interruption when hepatic enzyme levels are
greater than 3 × ULN with symptoms or jaundice, or
more than 5 × ULN in asymptomatic patients [6].
The timing and magnitude of elevations in the serum
transaminases over the course of treatment in all pa-
tients, with and without symptoms, remain unclear,
making appropriate management of liver toxicity, in-
cluding timing of treatment interruption and re-
introduction uncertain [6, 15, 16].
To address this evidence gap, we extracted data from a
large number of well-characterised patients with the aim of
describing the pattern of liver enzyme elevation in standard
TB therapy and identifying predisposing factors. We also
identified the timing and severity of liver enzyme elevation
in two experimental regimens. To our knowledge, this is
the largest and most comprehensive available analysis of
liver biochemical data for patients taking TB treatment.
Methods
REMoxTB database
All data were obtained from the double-blind placebo con-
trolled REMoxTB trial reported previously [17]. Patients
were over 18 years old with smear-positive pulmonary TB.
The treatment arms were: (i) a regimen of isoniazid (H), ri-
fampicin (R), ethambutol (E) and pyrazinamide (Z) for 8
weeks followed by 18 weeks of isoniazid and rifampicin
(2EHRZ/4HR); (ii) a regimen that replaced ethambutol with
moxifloxacin for 17 weeks (the isoniazid arm), followed by
9 weeks of placebo (2MHRZ/2MHR) and (iii) a regimen
that replaced isoniazid with moxifloxacin for 17 weeks (the
ethambutol arm), followed by 9 weeks of placebo (2EMRZ/
2MR). ALT or AST > 3 × ULN, total bilirubin > 2.5 ×
ULN, or Child–Pugh class C liver failure at screening were
exclusion criteria. Drug dosing was based on patient weight
at screening and can be found in Additional file 1: Table S1.
For this study, baseline characteristics, including the
presence or absence of cavities on a chest X-ray, were
collected. Liver biochemical tests (LBTs) were collected
for safety monitoring at screening and at weeks 2, 4, 8,
12 and 17 with additional tests carried out as required
clinically. In our analysis, we included all patients who
had received one or more doses of trial medication and
had LBTs measured at least twice.
Laboratory methods and data management
LBTs were performed in local laboratories and the nor-
mal ranges for each laboratory were used in this analysis.
LBT results from between 14 days before the first dose
of medication and 7 days after the last dose of trial
medication were included. Results for ALT, AST and
total bilirubin were expressed as multiples of the upper
limit of the local normal range (ULN).
In this study, DILI was defined as either ALT ≥ 5 ×
ULN or ALT ≥ 3 × ULN with total bilirubin >2 × ULN,
based on the 2011 international DILI Expert Working
Group consensus statement [18]. We considered all ALT
elevations ≥3 × ULN [with or without bilirubin eleva-
tions or increased international normalised ratio (INR)]
as clinically significant based on thresholds used by both
the ATS and BTS guidance [6, 13]. The trial adverse
event reporting system was used to obtain details of
symptoms at the time of DILI episodes and clinically sig-
nificant elevations by collecting all events within a time
window of 5 days before through to 5 days after the peak
ALT elevation. For patients with a peak ALT ≥ 3 × ULN,
serious adverse event narratives for the REMoxTB trial
were reviewed for information regarding treatment in-
terruptions, herbal medications, alcohol use and add-
itional tests carried out. Additionally, where sufficient
information was available, we applied the Roussel–Uclaf
causality assessment method (RUCAM) [19, 20] to iden-
tify a causal relationship between the TB medication and
peak ALT ≥ 3 × ULN. The criteria for the RUCAM
score can be found in Additional file 1: Table S2.
We searched the recorded adverse events for the terms
‘ascites’, ‘cirrhosis’, ‘child’, ‘hepatic’, and ‘liver’ and applied
the Child–Pugh scoring criteria (Additional file 1: Table
S3) to those patients with evidence of chronic liver dis-
ease within 1 month of their first dose of trial medica-
tion, to categorise those with stage A or B liver disease.
We identified all patients with ALT > 1 × ULN at
baseline and further ALT elevations on treatment. LBTs
in the database were labelled as having been taken either
at a protocol-scheduled visit or at an unscheduled visit
that was clinically indicated. For each treatment arm, we
calculated the proportion of LBTs that were taken at
scheduled visits compared to unscheduled tests for both
DILI cases and clinically significant elevations.
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Liver-related withdrawals were defined as patients
withdrawn from treatment following a peak ALT or AST
≥ 3 × ULN with only liver-related adverse events (either
clinical or relating to biochemical tests) recorded be-
tween their peak elevation and the time of withdrawal.
Patients who met these criteria were counted for all
three treatment arms.
Statistical methods
Data handling and statistical analysis were carried out using
Stata version 13.1 (StataCorp, Texas). A peak value for ALT,
AST, bilirubin and INR, along with the time in days from
first dose, was identified for each patient. The kappa test stat-
istic was used to assess agreement between ALTand AST.
The Mann–Whitney U test was used to investigate the
differences in the distribution of the peak ALT values
and the time to reach a peak value. Depending on the
number of patients in each group, the chi-squared or
Fisher’s exact test (if n ≤ 5 in any cell) was used to inves-
tigate the differences in peak values when grouped as ≥3
× ULN and <5 × ULN, ≥5 × ULN and <10 × ULN, and
≥10 × ULN. Comparisons made were either pairwise
comparing each experimental arm to standard therapy
(control), or isoniazid- or moxifloxacin-containing regi-
mens were combined and compared to the remaining
treatment regimen to investigate the effect of isoniazid.
Kaplan–Meier curves were constructed for the time
taken to reach peak ALT and AST for all patients in the
trial. We also constructed Kaplan–Meier curves for the
time taken to return to within the normal range for pa-
tients with a peak ALT or AST of >1 × ULN in all treat-
ment arms. The log-rank test was used to compare the
hazard functions between the experimental and standard
treatment arms for the events of interest (time to peak
and time to normalise) occurring at any time point.
Scatter plots were constructed to show the value and
timing of elevations in ALT and AST in each treatment
arm for patients with a peak value ≥3 × ULN.
Results
Liver enzyme results during treatment
Of the 1931 patients randomised in the trial, three pa-
tients were excluded from our analysis. A single patient
did not receive medication and two patients had only
one blood sample taken. Our final analysis population
consisted of 639 patients on standard TB therapy, 654
patients allocated to the isoniazid arm and 634 patients
on the ethambutol arm. We found 96% agreement
(kappa score of 0.58) between the peak ALT and AST re-
sults for patients with clinically significant elevations.
The peak value for ALT (0.78 and 0.73 vs 0.83 × ULN)
and AST (0.93 and 0.90 vs 1.02 × ULN) was found to be
significantly lower in the moxifloxacin-containing arms
compared to the standard therapy group (p < 0.05). Table 1
shows the peak ALT values and timings in the three treat-
ment arms with details of bilirubin elevations and INR
measurements for those patients with peak ALT ≥ 3 ×
ULN. The range of the median peak value for ALT and
AST for all patients varied between 0.73 × ULN to 1.02 ×
ULN across the treatment arms. The median ALT and AST
concentrations for all subjects at scheduled visits over 4
months are illustrated in Additional file 1: Figure S1.
Cases of DILI and clinically significant elevations
A total of 58 of 1928 (3.0%) patients met the criteria for
DILI defined in this analysis. This was made up of 22 of
639 (3.4%) patients taking standard therapy, 22 of 654
(3.4%) patients from the isoniazid arm and 14 of 634 (2.2%)
patients on the ethambutol arm (chi-squared p = 0.34). A
total of 101 of 1928 (5.2%) patients were considered to have
clinically significant ALT elevations of ≥3 × ULN. Across
the treatment arms, this was accounted for by 41 of 639
(6.4%) patients taking standard TB therapy, 35 of 654
(5.4%) patients on the isoniazid arm and 25 of 634 (3.9%)
patients on the ethambutol arm (chi-squared p = 0.13).
Among the 22 patients who met the criteria for DILI
on the standard therapy arm, eight patients reported
diarrhoea and/or vomiting, ten reported nausea and
three reported abdominal pain within 2 weeks of their
peak ALT value. Five patients reported diarrhoea and/or
vomiting and five patients had nausea among the DILI
patients on the isoniazid arm. Among DILI cases on the
ethambutol arm, two patients reported diarrhoea and/or
vomiting, one patient experienced nausea and two pa-
tients complained of abdominal pain. Out of the 101 pa-
tients with clinically significant ALT elevations, 11
patients complained of diarrhoea and/or vomiting, ten
reported nausea and one reported abdominal pain.
Additional hepatotoxic factors and causality assessment
The trial protocol did not mandate that viral hepatitis ser-
ology be checked in every instance of clinically significant
liver enzyme elevations and a majority of the patients were
not tested for hepatitis E serology. However, the trial med-
ical monitors strongly encouraged that this was performed
in all these cases. Serology results indicating acute hepa-
titis B infection were found in two DILI cases (one on
standard therapy and one on the ethambutol arm). Excess
alcohol use was reported in eight cases meeting the cri-
teria for clinically significant ALT elevations and DILI:
three patients from the standard arm, one patient from
the isoniazid arm and four patients from the ethambutol
arm. There was one confirmed instance of herbal medica-
tion use in a DILI patient on the ethambutol arm.
The RUCAM scoring system was applied to 18 pa-
tients with DILI. The overall median value for the score
was 8 out of 15 (interquartile range, IQR 4–9). The me-
dian values were 8 (IQR 3–8), 10.5 (IQR 3.5–13) and 7
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(IQR 4.5–8.5) for DILI cases on the standard, isoniazid
and ethambutol arms, respectively.
We identified one patient with Child–Pugh stage B
liver disease at the time of their randomisation onto the
isoniazid arm. This 24-year-old female patient was also
HIV positive and not receiving anti-retroviral therapy.
According to the database, the patient did not experi-
ence a recorded ALT or AST elevation >1 × ULN; how-
ever, she died after 45 days of treatment from ‘unclear
abdominal symptoms’ with no death certificate issued.
Timing of liver enzyme elevations
The median timing for ALT elevations can be seen in
Table 1 and the Kaplan–Meier curves in Fig. 1
demonstrate the time to peak ALT and AST levels for all
patients in the trial by treatment arm. There was no sta-
tistically significant difference on comparing the experi-
mental and standard arms for time to peak and for time
to normalise from a peak >1 × ULN (log-rank test, all p
values > 0.100).
At the time of randomisation, 183 patients had a
measured ALT > 1 × ULN and < 3 × ULN (65 pa-
tients from the standard arm, and 63 and 55 in the
isoniazid and ethambutol arms). Of these 183 pa-
tients, 11 (6%) went on to meet the criteria for DILI
on treatment (four patients taking standard therapy,
and four and three patients allocated to the isoniazid
and ethambutol arms).
Table 1 Summary of the numbers of patients with significant elevations in liver enzyme concentration (≥3 × ULN, ≥5 × ULN
and ≥10 × ULN) by treatment arm
Standard arm
(2EHRZ/4HR)
Isoniazid arm
(2MHRZ/2MHR)
Ethambutol arm
(2EMRZ/2MR)
p value
n1 634 649 634
Median peak ALT as × ULN (IQR) 0.83
(0.56–1.35)
0.78
(0.53–1.23)
0.73
(0.51–1.09)
0.0465
0.0006
Median time to peak ALT in arm (days) 28
(14–84)
28
(14–84)
55
(14–84)
0.9725
0.0176
Median time to peak ALT (days) if ≥3 × ULN 28
(14–56)
18
(14–56)
28
(27–56)
0.7555
0.6056
Median time to ALT < 1 × ULN2
(days)
26
(15–42)
28
(19–42)
39
(30–61)
0.5605
0.2706
No with peak ALT ≥ 3 × ULN and < 5 × ULN (%n3) 21
(3.3%)
17
(2.6%)
11
(1.7%)
0.2047
Bilirubin > 2 × ULN 2
(0.3%)
4
(0.6%)
0
(0.0%)
0.1427
INR4 >1.5 0
(0.0%)
3
(0.5%)
1
(0.2%)
0.0987
No with peak ALT ≥ 5 × ULN and < 10 × ULN (%n3) 13
(2.0%)
16
(2.4%)
11
(1.7%)
0.6567
Bilirubin > 2 × ULN 1
(0.2%)
2
(0.3%)
1
(0.2%)
0.7927
INR4 >1.5 0
(0.0%)
0
(0.0%)
0
(0.0%)
No with peak ALT ≥10 × ULN (%n3) 7
(1.1%)
2
(0.3%)
3
(0.5%)
0.1647
Bilirubin > 2 × ULN 2
(0.3%)
0
(0.0%)
1
(0.2%)
0.3607
INR4 >1.5 0
(0.0%)
0
(0.0%)
0
(0.0%)
No of liver-related withdrawals 11
(1.7%)
7
(1.1%)
4
(0.6%)
0.178
Median days from the start of treatment to reach individual patient peak concentrations and the number of patients withdrawing from treatment for liver-related
reasons are reported
ALT alanine aminotransferase, INR international normalised ratio, IQR interquartile range, ULN upper limit of normal
1 Some patients not included due to missing ALT results
2 If peak value ≥3 × ULN
3%n refers to percentage of total patients in the treatment arm
4 Patients with known anti-coagulant use were excluded from INR numbers
5 Isoniazid arm against standard therapy
6 Ethambutol arm against standard therapy
7 Chi-squared test (Fisher’s exact if any n ≤ 5)
Tweed et al. BMC Medicine  (2018) 16:46 Page 4 of 10
Of the 1917 peak ALT measurements that were included
in our analysis, a total of 38 were performed at unscheduled
visits carried out based on the clinical judgement of a local
physician. The median time for DILI was 28 days (IQR 14–
56), and 21 of the 58 (36.2%) cases were measured at un-
scheduled visits. Furthermore, 25 of the 101 (24.8%) clinic-
ally significant elevations were identified at unscheduled
visits at a median time of 25 days (IQR 14–56).
Enzyme elevations in patients receiving isoniazid
The proportion of patients with ALT and/or AST ≥ 3 ×
ULN was significantly higher in isoniazid-containing arms
(112 of 1293, 8.7%) than the ethambutol arm (38 of 635,
6.0%; p = 0.039). Similar percentages of patients had peak
ALT ≥ 5 × ULN: 3% in both the standard and isoniazid
arms and 2% in the ethambutol arm (see Table 1).
Patients in the ethambutol arm reached a peak ALT ≥
3 × ULN 9.5 days later than patients receiving the
isoniazid-containing regimens combined (median timing
28 days vs 18.5 days, p = 0.07). The median time to peak
ALT concentration in all patients was significantly
shorter in the two isoniazid-containing arms combined
(28 days vs 55 days, p = 0.004). The relationship between
peak value and the time that the peak occurred is dis-
played in Fig. 2 for patients with a peak value ≥3 × ULN
in all treatment arms.
Association of liver enzyme results with patient
characteristics
Table 2 shows the prevalence of patients in each
treatment arm who experienced a peak ALT or AST
(hereafter ALT/AST) ≥3 × ULN while taking their al-
located treatment, by subgroups defined by baseline
Fig. 1 Kaplan–Meier curves for time to reach peak in all patients and normalisation of elevated ALT and AST values for patients with peak ≥1 ×
ULN. The curves for the time to reach peak ALT and AST show for all patients the time to reach the peak enzyme level by treatment arm. The
log-rank test detected a significant difference for the time to reach peak ALT between the standard arm (median time 28 days) and ethambutol
arm (median time 55 days). The time for patients with peak ALT and AST > 1 × ULN to return to within the normal range from this peak is also
illustrated, with no significant difference detected between the treatment arms (p > 0.10). Eleven patients were not included in the time to peak
graphs, as the peak value was measured at the screening visit (visit 0). ALT alanine aminotransferase, AST aspartate aminotransferase, ULN upper
limit of normal
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characteristics. In the standard arm, the highest pro-
portion of patients with a peak ALT/AST ≥ 3 × ULN
was found in those aged >55 years with 8 of 38 pa-
tients (21.1%, p = 0.01).
Seven of 46 (15.2%) HIV-positive patients taking
standard therapy had elevated ALT/AST ≥ 3 × ULN
compared to 53 of 593 HIV-negative patients (8.9%) but
this difference was not significant (p = 0.160).
Fig. 2 Scatter plots illustrating peak values for ALT and AST in patients when peak value ≥3 × ULN. The timing in days since the first treatment
dose (x-axis) and peak ALT and AST (y-axis) is illustrated for each treatment arm for those patients with a peak ≥3 × ULN. The lines on the graphs
indicate the interquartile ranges for the peak ALT and AST and the timing of the peak in this subgroup, with shaded areas corresponding to the
interquartile range for both time and elevation result. Four patients excluded with ALT > 19 × ULN and six patients were excluded with AST >21
× ULN. ALT alanine aminotransferase, AST aspartate aminotransferase, ULN upper limit of normal
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Significantly more Asian patients experienced ALT/
AST ≥ 3 × ULN compared to other ethnic groups
[11.4% (Asian) vs 6.7% (black) vs 5.5% (mixed race), p
< 0.001]. Also, a significantly higher proportion of
Asian patients experienced DILI (28 of 560, 4.8%)
compared to the other ethnic groups (2.0% black, 0%
Caucasian, and 2.7% mixed race and other; p = 0.02).
Of the 67 Asian patients with a peak ALT/AST ≥ 3 ×
ULN, 57 (85.1%) were taking isoniazid-containing reg-
imens and 10 (14.9%) were allocated to the etham-
butol arm (p = 0.008).
Patients with extreme peak enzyme results
Seven of 639 (1.1%) on standard therapy exhibited a
peak ALT ≥ 10 × ULN (range 10.1–19.1 × ULN), and
among these patients, the median time to peak ALT was
29 days of therapy (IQR 7–52). Six of these patients were
male, the median age was 33.3 years (IQR 28.5–40.9
years) and two patients were HIV positive. Alcohol use
was confirmed as an underlying feature in two cases,
and one of these patients had positive serology for acute
hepatitis B. Most patients (5/7) reported nausea or
vomiting, and one reported abdominal pain within 2
weeks of the peak elevation.
Two patients in the isoniazid arm had peak ALT ≥ 10
× ULN (39.6 × ULN with bilirubin 1.7 × ULN and 11.9
× ULN at 17 and 56 days, respectively). Both were HIV
negative and less than 30 years old. No symptoms were
recorded for either of these patients.
In the ethambutol arm, three patients developed
peak ALT elevations of ≥10 × ULN (range 11.0–38.8
× ULN) with a range of 27–56 days. The median age
of the three patients was 42.5 years (range 39.5–49.5
years). There was one HIV-positive patient assigned
to the ethambutol arm, and the patient was not re-
ceiving anti-retroviral therapy. This patient, for whom
no predisposing conditions were identified, suffered a
severe and fatal course. Evidence of DILI arose after
2 weeks of treatment and they exhibited haemo-
dynamic compromise, a maculopapular rash and
symptoms of gastroenteritis. ALT peaked at 38.8 ×
ULN and total bilirubin at 6.2 × ULN. No post-
mortem was performed, with cause of death pro-
nounced as ‘hepatitis of unknown cause’.
Withdrawals due to liver toxicity
Out of 43 total deaths in the REMoxTB trial, only two
were linked to hepatotoxicity, as reported above. Only
22 patients were withdrawn from the trial due to liver-
related events (see Table 1), and none of these patients
died. Their mean age was 37 years (±13.96 years) and
73% were male. The median ALT peak in this group was
7.09 × ULN (IQR 2.83–10.05) occurring at 34.5 days,
and the median peak AST was 5.99 × ULN (IQR 3.03–
11.03) at 28.5 days. Of 22 patients, 10 (45.5%) had symp-
toms recorded; nine with diarrhoea and/or vomiting, six
reported nausea and one patient developed mild jaun-
dice. Seventeen of the 22 (77.3%) patients had achieved
a microbiological cure at 18 months, after onward refer-
ral to the National Treatment Programme.
Discussion
In this paper, we have shown that 94% of patients com-
pleted their course of standard TB therapy without clin-
ically significant ALT elevations detected. There were
Table 2 Relationship between elevation in liver enzyme
concentration and patient characteristics at baseline by
treatment regimen
Peak ALT or AST
≥3 × ULN1
Standard arm
(2EHRZ/4HR)
Isoniazid arm
(2MHRZ/2MHR)
Ethambutol arm
(2EMRZ/2MR)
n (%) 60 / 639 (9.4%) 52 / 654 (8.0%) 38 / 634 (6.0%)
Male (%) 40 / 447 (9.0%) 38 / 449 (8.5%) 24 / 447 (5.4%)
Female (%) 20 / 192 (10.4%) 14 / 205 (6.8%) 14 / 188 (7.5%)
Age in years2 (%)
18–24 13 / 186 (7.0%) 17 / 203 (8.4%) 11 / 172 (6.4%)
25–34 21 / 184 (11.4%) 11 / 213 (5.2%) 9 / 210 (4.3%)
35–44 16 / 142 (11.3%) 11 / 115 (9.6%) 8 / 122 (6.6%)
45–54 2 / 88 (2.3%) 6 / 81 (7.4%) 8 / 86 (9.3%)
≥55 8 / 38 (21.1%) 7 / 41 (17.1%) 2 / 44 (4.6%)
Baseline weight in kg (%)
<40 11 /63 (17.5%) 6 / 56 (10.7%) 5 / 56 (8.9%)
40–49 22 / 218 (10.1%) 20 / 243 (8.2%) 11 / 224 (4.9%)
50–59 16 / 242 (6.6%) 19 / 231 (8.2%) 12 / 236 (5.1%)
60–69 8 / 88 (9.1%) 5 / 88 (5.7%) 8 / 86 (9.3%)
≥70 3 / 28 (10.7%) 2 / 36 (5.6%) 2 / 33 (6.1%)
Ethnicity (%)
Black 20 / 295 (6.8%) 21 / 277 (7.6%) 17 / 290 (5.9%)
Asian 34 / 194 (17.5%) 23 / 201 (11.4%) 10 / 193 (5.18%)
Mixed race 6 /149 (4.0%) 8 / 174 (4.6%) 11 / 151 (7.3%)
Other 0 / 1 (0.0%) 0 / 2 (0.0%) 0 / 0 (0.0%)
HIV positive (%) 7 / 46 (15.2%) 3 / 46 (6.5%) 4 / 48 (8.3%)
HIV negative (%) 53 / 593 (8.9%) 49 / 608 (8.1%) 34 / 586 (5.8%)
Smoking history (%)
Never 31 / 298 (10.4%) 23 / 291 (7.9%) 16 / 279 (5.7%)
Previous 11 / 155 (7.1%) 17 / 155 (11.0%) 9 / 166 (5.4%)
Current 18 / 186 (9.7%) 12 / 208 (5.8%) 13 / 190 (6.8%)
Characteristics for patients across all treatment arms are shown according to
peak ALT and/or AST while taking treatment
ALT alanine aminotransferase, AST aspartate aminotransferase, ULN upper limit
of normal
1 Cell percentages shown
2 Data for date of birth was not available for some patients in all three
treatment arms
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similar proportions of 95% in the isoniazid arm and 96%
in the ethambutol arm.
There has been an assumption that the majority of eleva-
tions during TB treatment will occur within the first 2 to 4
weeks of therapy. One recent paper reported that over half
of the patients who developed elevated liver enzymes within
2 weeks of starting treatment had good specificity for pre-
dicting hepatotoxicity later during treatment using a moni-
toring schedule of regular testing for the first 2 weeks of
treatment [16]. The BTS and ATS [6, 13] both recommend
pre-treatment baseline blood tests followed by clinical as-
sessment in all patients. In patients deemed by the phys-
ician to be at higher risk of DILI or with existing liver
disease or age > 35 years old, the ATS recommends a fur-
ther blood test between 2 and 4 weeks after initiating ther-
apy [6]. The BTS advises a policy of further weekly blood
tests for 2 weeks and 2-weekly blood tests for the first 2
months for patients with known liver dysfunction. Current
guidance from the World Health Organization does not in-
clude regular monitoring for hepatotoxicity, and instead
symptoms are used to detect liver dysfunction [21].
In REMoxTB, the IQR for the time to reach peak ALT
≥ 3 × ULN was 14–56 days for patients taking standard
TB therapy, suggesting that 75% of these patients would
have been detected by a regular LBT during the first 60
days of treatment. Based on the pattern of elevations ob-
served, we would recommend a monitoring schedule
consisting of LBTs at baseline, 1 week (to identify early
elevators), 2 weeks (lower end of the IQR), 4 weeks (me-
dian timing for elevations) and 8 weeks (upper end of
the IQR). We suggest that this schedule is achievable
even in resource-poor settings and that our findings sug-
gest diminishing return for LBTs after 8 weeks of ther-
apy in the absence of symptoms.
There are unanswered questions surrounding the sig-
nificance of isolated ALT elevations regarding how best
to evaluate these patients, and which are the most ap-
propriate biochemical markers to be included in the
evaluation of ALT elevations [22]. Isolated liver enzyme
levels on treatment could reflect hepatic adaptation to
the medication, wherein transient LBT abnormalities re-
solve even with continued exposure to the drug and the
patient remains clinically well throughout [23]. One
large cohort study of over 11,000 patients receiving iso-
niazid preventive therapy observed symptoms and signs
of hepatotoxicity in only 0.15% of patients completing
therapy [24], suggesting that the rates of DILI/enzyme
elevations requiring intervention are actually very low
with monotherapy and, by extension, with standard TB
therapy as well. Certainly, in our study a minority of pa-
tients with DILI or clinically significant elevations had
recorded symptoms or bilirubin elevations and in the
trial, the majority of patients who experienced liver en-
zyme elevations went on to be cured of their disease.
A prospective series of 1223 patients with drug-induced
liver failure demonstrated that TB therapy-induced liver
failure can often have a subacute presentation and was as-
sociated with 67% mortality [25]. The fatality seen on the
ethambutol arm involving an ALT rise of 38 × ULN high-
lights the risk of mortality for patients presenting with
hyperbilirubinaemia and elevated levels of liver enzymes.
While the local physician evaluated this as ‘hepatitis of un-
known cause’, it would seem reasonable to consider this as
DILI. By comparison, the mortality associated with acute
viral hepatitis is low and the majority of deaths are
accounted for by the chronic sequelae of the disease [26].
Despite most patients being clinically unaffected by ALT
elevations on treatment, we still demonstrated an overall risk
of 3.4% for DILI on standard TB therapy and higher rates of
DILI among those patients with enzyme elevations at ran-
domisation compared with the overall trial population. Given
the challenging circumstances surrounding TB treatment
(with much higher levels of HIV co-infection than seen in
REMoxTB), we would still recommend the conservative
monitoring schedule laid out above to allow for the early de-
tection of at-risk patients. Given that the majority of patients
with liver enzyme elevations were not withdrawn, there is
some evidence in favour of attempting to re-introduce the
same regimen following a treatment interruption, as opposed
to immediately changing to a more liver-sparing regimen.
An association between significant hepatic events sec-
ondary to TB treatment and HIV-positive status has
been reported previously [6, 27–29]. However, the pre-
cise magnitude of this risk is not clear. The observed
higher rate of ALT/AST elevations in HIV-positive indi-
viduals in this study is similar to that in other reports
[27–29], although this did not achieve statistical signifi-
cance in our study. Lower CD4+ counts have been sig-
nificantly associated with risk for sub-clinical
hepatotoxicity in HIV-positive individuals on TB therapy
[30]. Exclusion from the trial of patients with CD4 < 250
cells/μL may have reduced the rates of hepatotoxicity.
Our data support the increased risk of hepatotoxicity
in certain ethnic groups [31, 32], and in our study, we
found evidence to support a higher risk of liver enzyme
elevations in Asian patients. Polymorphisms affecting
the cytochrome P450 and NAT2 liver enzymes are asso-
ciated with an increased risk of hepatotoxicity, and
NAT2 is especially related to the metabolism of isoniazid
[33–35]. However, it needs to be remembered that there
may be factors unique to individual sites that confound
the relationship between ethnicity and liver function
changes, such as alcohol use and viral hepatitis.
Additionally, although based on small numbers, we have
seen a higher proportion of older patients experiencing
enzyme elevations when taking standard TB therapy.
After observing unacceptably high rates of significant
hepatotoxicity associated with the use of rifampicin and
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pyrazinamide to treat latent TB infection [36, 37], a pro-
tective effect of isoniazid on the liver was hypothesised by
some as a possible explanation [38, 39]. In REMoxTB,
those patients taking isoniazid-containing regimens ex-
hibit significantly higher and earlier peak ALT and AST
values on treatment. Combined with the significantly
lower peak values seen in the moxifloxacin-containing
arms (lowest in the ethambutol arm), this supports the
use of moxifloxacin in liver-sparing regimens. Specifically,
the low rate of enzyme elevations in the ethambutol arm
could suggest a role for this as a liver-sparing regimen, but
more work is needed to investigate the ideal duration [17].
Clinical trials are not fully representative of the diver-
sity of TB patients as CD4 and liver enzyme criteria
were set for admission. Early in the REMoxTB study,
only AST was measured, and not ALT, which led to ab-
sent ALT results for some patients. The study protocol
did not call for alkaline phosphate measurements and
we were, therefore, unable to apply fully the criteria for
Hy’s law to clinically significant enzyme elevations. The
timings of temporary medication pauses were also not
recorded with sufficient accuracy in the database.
Conclusions
In conclusion, we show that older age (on standard ther-
apy), Asian ethnicity and the presence of isoniazid in a
treatment regimen are significantly associated with liver
enzyme elevations during treatment. Closer monitoring
of these patients during treatment may be beneficial,
and there is justification for the exclusion of isoniazid
from liver-sparing regimens. Despite relatively high rates
of liver enzyme elevations, the majority of patients com-
pleted the course of their treatment with a high cure rate
in the standard therapy. Standard TB therapy is lengthy
and toxic, and this work further emphasises the need to
develop shorter, effective and better-tolerated treatment
to combat the ongoing global epidemic of TB.
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